Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 56
Filter
1.
Transl Oncol ; 14(8): 101132, 2021 Aug.
Article in English | MEDLINE | ID: mdl-34051621

ABSTRACT

BACKGROUND: Liquid Biopsy (LB) in the form of e.g., circulating tumor cells (CTCs) is a promising non-invasive approach to support current therapeutic cancer management. However, the proof of clinical utility of CTCs in informing therapeutic decision-making for e.g., breast cancer in clinical trials and associated translational research projects is facing the issues of low CTC positivity rates and low CTC numbers - even in the metastasized situation. To compensate for this dilemma, clinical CTC trials are designed as large multicenter endeavors with decentralized sample collection, processing and storage of products, making data management highly important to enable high-quality translational CTC research. AIM: In the DETECT clinical CTC trials we aimed at developing a custom-made, browser-based virtual database to harmonize and organize both decentralized processing and storage of LB specimens and to enable the collection of clinically meaningful LB sample. METHODS: ViBiBa processes data from various sources, harmonizes the data and creates an easily searchable multilayered database. RESULTS: An open-source virtual bio-banking web-application termed ViBiBa was created, which automatically processes data from multiple non-standardized sources. These data are automatically checked and merged into one centralized databank and are providing the opportunity to extract clinically relevant patient cohorts and CTC sample collections. SUMMARY: ViBiBa, which is a highly flexible tool that allows for decentralized sample storage of liquid biopsy specimens, facilitates a solution which promotes collaboration in a user-friendly, federalist and highly structured way. The source code is available under the MIT license from https://vibiba.com or https://github.com/asperciesl/ViBiBa.

2.
Oncogene ; 36(23): 3223-3231, 2017 06 08.
Article in English | MEDLINE | ID: mdl-28068321

ABSTRACT

Direct analysis of circulating tumor cells (CTCs) can inform on molecular mechanisms underlying systemic spread. Here we investigated promoter methylation of three genes regulating epithelial-to-mesenchymal transition (EMT), a key mechanism enabling epithelial tumor cells to disseminate and metastasize. For this, we developed a single-cell protocol based on agarose-embedded bisulfite treatment, which allows investigating DNA methylation of multiple loci via a multiplex PCR (multiplexed-scAEBS). We established our assay for the simultaneous analysis of three EMT-associated genes miR-200c/141, miR-200b/a/429 and CDH1 in single cells. The assay was validated in solitary cells of GM14667, MDA-MB-231 and MCF-7 cell lines, achieving a DNA amplification efficiency of 70% with methylation patterns identical to the respective bulk DNA. Then we applied multiplexed-scAEBS to 159 single CTCs from 11 patients with metastatic breast and six with metastatic castration-resistant prostate cancer, isolated via CellSearch (EpCAMpos/CKpos/CD45neg/DAPIpos) and subsequent FACS sorting. In contrast to CD45pos white blood cells isolated and processed by the identical approach, we observed in the isolated CTCs methylation patterns resembling more those of epithelial-like cells. Methylation at the promoter of microRNA-200 family was significantly higher in prostate CTCs. Data from our single-cell analysis revealed an epigenetic heterogeneity among CTCs and indicates tumor-specific active epigenetic regulation of EMT-associated genes during blood-borne dissemination.


Subject(s)
Biomarkers, Tumor/genetics , Breast Neoplasms/genetics , DNA Methylation , Neoplastic Cells, Circulating/pathology , Prostatic Neoplasms, Castration-Resistant/genetics , Single-Cell Analysis/methods , Antigens, CD , Breast Neoplasms/pathology , Cadherins/genetics , Epigenesis, Genetic , Epithelial-Mesenchymal Transition , Female , Humans , Male , MicroRNAs/genetics , Prostatic Neoplasms, Castration-Resistant/pathology , Tumor Cells, Cultured
3.
Dis Markers ; 2016: 7861919, 2016.
Article in English | MEDLINE | ID: mdl-27563165

ABSTRACT

Objective. The purpose of this prospective study was to investigate the predictive value of single prepartum findings combined with serum biomarkers sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor) indicating severity of preeclampsia (PE) for occurrence and extent of impaired postpartum kidney function. Study Design. In this prospective, single center study 44 PE patients were compared to 39 healthy controls (similar in age and gestational age with singleton pregnancy) evaluated at time of delivery and at 6 months and 12 months postpartum. p values below 0.05 are considered statistically significant. Results. The majority of the PE patients had persistence of proteinuria (>120 mg/L after delivery) 6 months (p = 0.02) and 12 months postpartum (p < 0.0001) compared to controls. Also reduced GFR (glomerular filtration rate) persisted up to 6 months postpartum in PE patients compared to controls (p < 0.001). Prepartum sFlt-1 levels indeed correlated with impaired renal function parameters. Conclusion. A significant proportion of our PE patients had lower GFR levels and persistent proteinuria up to 12 months postpartum. Prepartum sFlt-1 is a trend-setting marker for impaired renal function postpartum, but it is not sufficient enough to predict renal impairment after PE. An evaluation of 24-month follow-up data is scheduled.


Subject(s)
Biomarkers/metabolism , Placenta Growth Factor/metabolism , Postpartum Period , Pre-Eclampsia/physiopathology , Renal Insufficiency/diagnosis , Vascular Endothelial Growth Factor Receptor-1/metabolism , Adult , Case-Control Studies , Female , Follow-Up Studies , Germany/epidemiology , Glomerular Filtration Rate , Humans , Kidney Function Tests , Predictive Value of Tests , Pregnancy , Prevalence , Prospective Studies , Renal Insufficiency/epidemiology , Renal Insufficiency/metabolism , Young Adult
4.
Geburtshilfe Frauenheilkd ; 75(3): 232-237, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25914415

ABSTRACT

Circulating tumor cells (CTCs) can be detected in the peripheral blood of breast cancer patients with early and metastatic disease. Recent data suggest that immune pathologic characteristics between the primary tumor, metastatic colonies and CTCs are discordant and that CTCs possess an independent phenotype that is associated with prognosis and treatment efficacy. Large scale gene expression analysis has provided the possibility to stratify breast cancer according to the gene expression fingerprint of primary tumor tissue into five intrinsic molecular subtypes which can be associated with different clinical outcome. As a consequence of the different prognostic power of primary tumors' characteristics and CTCs several groups have started to investigate if CTCs might be disseminated differentially within these breast cancer subtypes. They determined the CTC number in immunohistochemical subtypes to validate if CTCs may provide differential and more specific prognostic information within each subtype. This review provides an overview of the outcome of some recently published data gathered from early and metastatic breast cancer.

5.
Biomed Res Int ; 2014: 379847, 2014.
Article in English | MEDLINE | ID: mdl-24804218

ABSTRACT

The actin binding protein CapG modulates cell motility by interacting with the cytoskeleton. CapG is associated with tumor progression in different nongynecologic tumor entities and overexpression in breast cancer cell lines correlates with a more invasive phenotype in vitro. Here, we report a significant CapG overexpression in 18/47 (38%) of ovarian carcinomas (OC) analyzed by qRealTime-PCR analyses. Functional analyses in OC cell lines through siRNA mediated CapG knockdown and CapG overexpression showed CapG-dependent cell migration and invasiveness. A single nucleotide polymorphism rs6886 inside the CapG gene was identified, affecting a CapG phosphorylation site and thus potentially modifying CapG function. The minor allele frequency (MAF) of SNP rs6886 (c.1004A/G) was higher and the homozygous (A/A, His335) genotype was significantly more prevalent in patients with fallopian tube carcinomas (50%) as in controls (10%). With OC being one of the most lethal cancer diseases, the detection of novel biomarkers such as CapG could reveal new diagnostic and therapeutic targets. Moreover, in-depth analyses of SNP rs6886 related to FTC and OC will contribute to a better understanding of carcinogenesis and progression of OC.


Subject(s)
Biomarkers, Tumor , Cell Movement/genetics , Microfilament Proteins , Nuclear Proteins , Oncogene Proteins , Ovarian Neoplasms , Polymorphism, Single Nucleotide , Adolescent , Adult , Aged , Aged, 80 and over , Alleles , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Cell Line, Tumor , Fallopian Tube Neoplasms/genetics , Fallopian Tube Neoplasms/metabolism , Fallopian Tube Neoplasms/pathology , Female , Gene Frequency/genetics , Humans , Microfilament Proteins/genetics , Microfilament Proteins/metabolism , Middle Aged , Neoplasm Invasiveness , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Oncogene Proteins/genetics , Oncogene Proteins/metabolism , Ovarian Neoplasms/genetics , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Phosphorylation/genetics , Real-Time Polymerase Chain Reaction
6.
J Med Genet ; 46(4): 254-8, 2009 Apr.
Article in English | MEDLINE | ID: mdl-18996907

ABSTRACT

BACKGROUND: Increasingly women at high risk of breast cancer are opting for risk reducing surgery. The aim of this study was to assess the effectiveness of this approach in women at high risk in both carriers and non-carriers of BRCA1/2. METHODS: Data from 10 European centres that offer a genetic counselling and screening service to women at risk were obtained prospectively from 1995. Breast cancer risks were estimated from life tables and a control group of women at risk who did not undergo surgery. RESULTS: The combined centres have data on 550 women who have undergone risk reducing mastectomy with greater than 3334 women years of follow-up. Operations were carried out on women with lifetime risks of 25-80%, with an average expected incidence rate of 1% per year. No breast cancers have occurred in this cohort in the "at risk" unaffected breast, whereas >34 would have been expected. A high rate (2-3.6%) of occult disease was identified in the at risk breast at the time of surgery. INTERPRETATION: We conclude that risk reducing surgery is highly effective.


Subject(s)
Breast Neoplasms/surgery , Mastectomy/methods , Adult , Aged , BRCA1 Protein/genetics , BRCA2 Protein/genetics , Breast Neoplasms/epidemiology , Breast Neoplasms/genetics , Europe/epidemiology , Female , Follow-Up Studies , Genetic Counseling , Genetic Testing , Humans , Incidence , Middle Aged , Ovariectomy , Risk Factors , Young Adult
7.
Br J Cancer ; 99(6): 974-7, 2008 Sep 16.
Article in English | MEDLINE | ID: mdl-18781154

ABSTRACT

The close functional relationship between p53 and the breast cancer susceptibility genes BRCA1 and BRCA2 has promoted the investigation of various polymorphisms in the p53 gene as possible risk modifiers in BRCA1/2 mutation carriers. Specifically, two polymorphisms in p53, c.97-147ins16bp and p.Arg72Pro have been analysed as putative breast cancer susceptibility variants, and it has been recently reported that a p53 haplotype combining the absence of the 16-bp insertion and the presence of proline at codon 72 (No Ins-72Pro) was associated with an earlier age at the onset of the first primary tumour in BRCA2 mutation carriers in the Spanish population. In this study, we have evaluated this association in a series of 2932 BRCA1/2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1 and BRCA2.


Subject(s)
BRCA1 Protein/genetics , BRCA2 Protein/genetics , Breast Neoplasms/genetics , Germ-Line Mutation/genetics , Polymorphism, Genetic/genetics , Tumor Suppressor Protein p53/genetics , Adult , Breast Neoplasms/pathology , Female , Genetic Predisposition to Disease , Genotype , Haplotypes , Heterozygote , Humans , Ovarian Neoplasms/genetics , Ovarian Neoplasms/pathology , Risk Factors
8.
Oncogene ; 25(24): 3479-88, 2006 Jun 08.
Article in English | MEDLINE | ID: mdl-16449975

ABSTRACT

The canonical Wnt signalling pathway plays a key role during embryogenesis and defects in this pathway have been implicated in the pathogenesis of various types of tumours, including breast cancer. The gene for secreted frizzled-related protein 1 (SFRP1) encodes a soluble Wnt antagonist and is located in a chromosomal region (8p22-p12) that is often deleted in breast cancer. In colon, lung, bladder and ovarian cancer SFRP1 expression is frequently inactivated by promoter methylation. We have previously shown that loss of SFRP1 protein expression is a common event in breast tumours that is associated with poor overall survival in patients with early breast cancer. To investigate the cause of SFRP1 loss in breast cancer, we performed mutation, methylation and expression analysis in human primary breast tumours and breast cell lines. No SFRP1 gene mutations were detected. However, promoter methylation of SFRP1 was frequently observed in both primary breast cancer (61%, n=130) and cell lines analysed by methylation-specific polymerase chain reaction (MSP). We found a tight correlation (P<0.001) between methylation and loss of SFRP1 expression in primary breast cancer tissue. SFRP1 expression was restored after treatment of tumour cell lines with the demethylating agent 5-aza-2'-deoxycytidine. Most interestingly, SFRP1 promoter methylation was an independent factor for adverse patient survival in Kaplan-Meier analysis. Our results indicate that promoter hypermethylation is the predominant mechanism of SFRP1 gene silencing in human breast cancer and that SFRP1 gene inactivation in breast cancer is associated with unfavourable prognosis.


Subject(s)
Breast Neoplasms/genetics , DNA Methylation , Gene Expression Regulation, Neoplastic , Gene Silencing , Glycoproteins/genetics , Adult , Aged , Aged, 80 and over , Breast Neoplasms/metabolism , Cell Line, Tumor , Epigenesis, Genetic , Female , Humans , Intracellular Signaling Peptides and Proteins , Middle Aged , Wnt Proteins/metabolism
9.
Eur J Cancer Prev ; 14(4): 399-411, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16030432

ABSTRACT

A prospective follow-up study was carried out to evaluate the influence of risk and genetic counselling on use of early cancer detection. Five hundred and fifty-six subjects who fulfilled inclusion criteria for a genetic analysis of the BRCA1/2 genes (the high-risk group A) and 205 who did not fulfil the inclusion criteria (the lower risk group B) attended primary consultation in the interdisciplinary cancer genetic clinic. Information about participation in the early cancer detection programme was documented. Information about changes in use after consultation could be evaluated from 349 women (94 group B and 255 group A). Methods such as monthly self-palpation, breast palpation by gynaecologist, ultrasound of the breast, transvaginal ultrasound and pelvic examination had all been commonly used. Consultees at higher risk used mammography less often than women at lower risk. Magnetic resonance imaging of the breast was used rarely. Most methods were used more often at the recommended interval by women at higher risk during the follow-up period. In conclusion, at present intensified early cancer detection programmes for women at risk provide a less invasive option than chemoprevention or prophylactic surgery. Although the methods are used at high frequency it seems feasible to motivate women at risk to participate. This can be done by providing information and counselling in the cancer genetic clinic.


Subject(s)
Breast Neoplasms/epidemiology , Breast Neoplasms/genetics , Heterozygote , Mass Screening/organization & administration , Ovarian Neoplasms/epidemiology , Ovarian Neoplasms/genetics , Adult , Age Distribution , Aged , BRCA1 Protein/genetics , BRCA2 Protein/genetics , Breast Neoplasms/diagnosis , Early Diagnosis , Female , Genetic Testing , Germany/epidemiology , Humans , Incidence , Mammography/methods , Middle Aged , Ovarian Neoplasms/therapy , Patient Compliance , Pedigree , Probability , Risk Assessment , Surveys and Questionnaires , Survival Rate
10.
Z Kardiol ; 93(4): 300-9, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15085375

ABSTRACT

Parvovirus B19 (PB19) has been identified as a possible cause of myocarditis and heart failure in both children and adult patients. This study used real time PCR analysis, to determine the frequency and to quantify PB19 viral genomes in endomyocardial tissue samples from 80 adult patients with clinically suspected myocarditis or idiopathic left ventricular dysfunction and from 36 controls. Histological (Dallas classification) and immunohistological analyses were performed to detect myocardial inflammation in the endomyocardial biopsies.PB19 genomic DNA was found in nine of 80 patients (11.2%), 4 out of 31 (12.9%) patients with inflammatory infiltrates detected via immunohistological methods and 5 out of 49 (10.2%) patients with left ventricular dysfunction without myocardial inflammation. The copy numbers for PB19 DNA ranged between 30 and 3900 per microg of cellular DNA. Four patients with clinically suspected myocarditis had copy numbers for PB19 DNA of 70, 740, 3400 and 3900, respectively, per microg of cellular DNA in the endomyocardial biopsy. Five patients with idiopathic left ventricular dysfunction had copy numbers for PB19 DNA of 30, 38, 52, 58 and 90, respectively, per microg of cellular DNA in the endomyocardial biopsy. The amplicon of one of the nine positive PCR fragment was sequenced and was found to be fully identical in the highly conserved sequence of published Parvovirus B19 VP1/VP2 genes (NCBI gene bank). In all patients, acute myocarditis was excluded according to the Dallas classification. All biopsies of 36 controls with no history of myocarditis or recent viral infection were negative for myocardial inflammation and parvovirus B19 genomes. In summary, Parvovirus B19 DNA is present within the myocardium of patients with suspected myocarditis and idiopathic left ventricular dysfunction and can be detected and quantified in endomyocardial specimens via real time PCR.


Subject(s)
Myocarditis/epidemiology , Myocarditis/virology , Parvoviridae Infections/epidemiology , Parvoviridae Infections/genetics , Parvovirus B19, Human/genetics , Parvovirus B19, Human/isolation & purification , Ventricular Dysfunction, Left/embryology , Ventricular Dysfunction, Left/virology , Adult , Aged , Comorbidity , Endocardium/pathology , Endocardium/virology , Female , Genome, Viral , Germany/epidemiology , Humans , Male , Middle Aged , Myocarditis/pathology , Polymerase Chain Reaction , Prevalence , Risk Assessment/methods , Risk Factors , Ventricular Dysfunction, Left/pathology
11.
J Steroid Biochem Mol Biol ; 88(2): 131-42, 2004 Feb.
Article in English | MEDLINE | ID: mdl-15084345

ABSTRACT

The physiological effects of progesterone are mediated by the progesterone receptor (PR) isoforms PRA and PRB, transcribed from a single gene, under control of two distinct promoters. Both the isoforms display different, promoter- and cell line-specific transactivation properties. Upregulation of both isoforms in response to estradiol stimulation has been described, although the two promoters contain no classical estrogen response element (ERE). Therefore, we decided to investigate the regulation of PRB-expression through distinct estrogen receptor (ER)-isoforms: ERalpha and ERbeta We demonstrate, that in HeLa cells treated with E2, PRB promoter activity was enhanced (five-fold) by ERalpha, but not by ERbeta. ERbeta was also unable to stimulate activity of the PRB promoter in BT20 and Ishikawa cells, where ERalpha induced reporter activity by two-fold. Deletion of the AF1-but not AF2 domain from ERalpha resulted in loss of the transactivation potential in all cell lines tested. Furthermore, in BT20 cells deletion of the AF2 domain of ERalpha resulted in stronger transcriptional activation than that mediated through wild-type ERalpha. In SK-BR-3 cells both ERs repressed PRB promoter activity and this repression was enhanced by co-transfection of SRC1. However, strong estrogen-dependent stimulation was observed after deletion of AF2. We conclude that PRB expression is stimulated by ERalpha but not ERbeta in an unique, AF1-dependent but AF2-independent mechanism.


Subject(s)
Estradiol/pharmacology , Gene Expression Regulation/drug effects , Receptors, Estrogen/physiology , Receptors, Progesterone/genetics , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Estrogen Receptor alpha , HeLa Cells , Humans , Promoter Regions, Genetic , Transcriptional Activation
12.
Eye (Lond) ; 18(7): 729-33, 2004 Jul.
Article in English | MEDLINE | ID: mdl-14739915

ABSTRACT

PURPOSE: Lack of Oestrogen and androgen may be of importance in the pathogenesis of keratoconjunctivitis sicca (KCS). The signal of Oestrogens is transmitted via specific Oestrogen receptors (ER). It was the purpose of this study to evaluate the expression of ER alpha and ER beta in tear-producing tissues. METHODS: Reverse transcriptase-polymerase chain reaction (RT-PCR, ER alpha + beta) and immunohistochemical evaluation (ER alpha only) were performed for ER detection and localization in tissue samples of bulbar conjunctiva (20 samples of 20 patients undergoing cataract surgery), tarsal plates (14 samples of 12 patients undergoing eye lid surgery), and lacrimal glands (20 samples of 13 cornea donors). RESULTS: Messenger RNA ER alpha was identified via RT-PCR in all tissue samples with variable expression, ER beta predominantly in lacrimal gland tissue. Immunohistochemical staining for ER alpha was negative in most cases, probably due to the thermolability of ERs and very small sample sizes. CONCLUSIONS: The detection of ER alpha and ER beta mRNA expression supports the concept of a receptor-based effect of Oestrogen in these tissues contributing to KCS. This may encourage therapeutical efforts including topical Oestrogen administration.


Subject(s)
Eye/metabolism , Receptors, Estrogen/metabolism , Adult , Aged , Aged, 80 and over , Aging/metabolism , Conjunctiva/metabolism , Estrogen Receptor alpha , Estrogen Receptor beta , Eyelids/metabolism , Female , Gene Expression , Humans , Keratoconjunctivitis Sicca/metabolism , Lacrimal Apparatus/metabolism , Male , Middle Aged , RNA, Messenger/genetics , Receptors, Estrogen/genetics , Reverse Transcriptase Polymerase Chain Reaction
13.
J Cancer Res Clin Oncol ; 129(3): 161-4, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12712331

ABSTRACT

PURPOSE: Interactions of hyaluronic acid (HA) with its binding protein RHAMM (receptor for HA-mediated motility) have been proposed as being important in promoting tumour progression and dissemination. This comparative study was designed to investigate the RHAMM expression patterns in endometrial carcinoma. METHODS: We examined a series of 89 endometrial carcinomas and 15 normal endometrial tissues by immunohistochemistry, using a RHAMM-specific polyclonal antibody. Expression of RHAMM was assessed according to the pattern and intensity within (overall cytoplasm, center/periphery of tumours) and between the tumours. The staining results were compared to the corresponding clinical data (age, menopause status, histological staining, histological grading, lymph node status). RESULTS: RHAMM-expression was detectable in 58% of the 89 tumours [Histological stage: pT1a (8/12); pT1b (16/37); pT1c (18/26); pT2 (6/9); pT3a (4/5)] and 13% (2/15) of the normal endometrial tissues. The positivity rates for RHAMM were 100% in patients with positive lymph nodes but only 50.7% in patients with negative lymph nodes ( P<0-01). Additionally, the expression pattern showed a highly significant correlation ( P<0.01) with the histological grade of the tumours [G1 (6/42), G2 (33/34), G3 (13/13)] and occurrence of lymph node metastases. CONCLUSIONS: Our results suggest that RHAMM expression may enhance and improve the invasion and metastasis of endometrial carcinomas.


Subject(s)
Endometrial Neoplasms/metabolism , Extracellular Matrix Proteins/metabolism , Hyaluronan Receptors/metabolism , Adenocarcinoma, Clear Cell/metabolism , Adenocarcinoma, Clear Cell/pathology , Adenocarcinoma, Papillary/metabolism , Adenocarcinoma, Papillary/pathology , Carcinosarcoma/metabolism , Carcinosarcoma/pathology , Case-Control Studies , Cell Division , Cystadenocarcinoma, Serous/metabolism , Cystadenocarcinoma, Serous/pathology , Endometrial Neoplasms/pathology , Endometrium/metabolism , Female , Humans , Immunoenzyme Techniques , Lymphatic Metastasis , Middle Aged , Neoplasm Invasiveness , Prognosis , Survival Rate
14.
Horm Metab Res ; 33(8): 451-7, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11544557

ABSTRACT

Proliferation of breast and endometrial cells is under the control of ovarian steroid hormones (SHs) such as oestrogen and progesterone. They mediate diverse physiological functions via interaction with nuclear-localised steroid hormone receptors (HRs). The SH receptor complex modifies the expression of SH-regulated genes by binding to conserved binding sites in their promoter region or through cross-talk with other transcription factors. In non-malignant tissues, HRs are in balance with other factors regulating proliferation, differentiation and apoptosis. While dysfunction of the regulatory mechanisms is a part of malignant transformation, functional SH receptors can promote growth of SH-responsive tumours. Therefore, anti-hormones that block the interaction of steroid hormones with the SH receptor are useful tools for the treatment of SH-responsive carcinomas. However, a portion of ER-positive breast cancers and most endometrial cancers do not respond to anti-oestrogens and continued treatment results in hormone resistance, mostly without loss of the ER. This review focuses on the mechanisms of action of hormones and anti-hormones in breast and endometrial carcinomas.


Subject(s)
Breast Neoplasms/metabolism , Endometrial Neoplasms/metabolism , Estrogen Receptor Modulators/metabolism , Estrogens/metabolism , Receptors, Estrogen/metabolism , Animals , Binding Sites/physiology , Breast Neoplasms/drug therapy , Disease Progression , Endometrial Neoplasms/drug therapy , Estrogen Receptor Modulators/therapeutic use , Female , Gene Expression/physiology , Hormone Antagonists/metabolism , Hormones/metabolism , Humans , Receptor Cross-Talk/physiology , Receptors, Steroid/metabolism , Steroids/metabolism , Transcription Factors/metabolism
15.
Oncol Rep ; 8(5): 987-93, 2001.
Article in English | MEDLINE | ID: mdl-11496303

ABSTRACT

The expression of distinct variant isoforms of the cell surface glycoprotein CD44 (CD44v) has been found to be associated with metastatic potential of rodent adenocarcinoma cells and with an altered prognosis in several types of human cancer. In hormone-dependent gynecological cancers, different CD44v expression patterns have been observed. The influence of ovarian steroid hormones and their antagonists on CD44v expression is still unclear, since there are only retrospective correlation studies so far. Therefore, we examined the CD44 mRNA expression in a standardized stimulation experiment in a number of breast and endometrial carcinoma cell lines varying in estrogen receptor (ER) status. Higher CD44 overall expression was observed in ER positive endometrial and breast carcinoma cell lines when compared to corresponding ER negative cell lines. The number and composition of alternatively spliced isoforms showed no clear correlation to the ER expression status. Three CD44v isoforms were detected in all cell lines expressing CD44v, two of which have not been reported previously in normal endometrial cells. These isoforms may have specific functions in this type of carcinoma. In the second part of the study, the influence of (anti-) hormones on CD44 expression in endometrial carcinoma cell lines was examined. CD44 overall expression showed an increase when the cells were grown in medium containing fetal calf serum (FCS) as compared to cells maintained in medium-free of FCS. CD44 expression was transiently increased by estradiol (1 h). The CD44 splice pattern of endometrial cancer cell lines RL95-2 and Hec-1-A, after treatment with (anti-) hormones showed constant and high expression rates for distinct CD44v-isoforms such as CD44E (CD44v8-v10). Only certain weakly expressed isoforms changed their expression level during the experimental period, but no direct correlation to hormone treatment was observed. In conclusion, estradiol or FCS increase CD44 overall expression, but there seems to be no direct influence of ovarian steroid hormones on the CD44v splice machinery in endometrial carcinoma cell lines.


Subject(s)
Antineoplastic Agents, Hormonal/pharmacology , Breast Neoplasms/metabolism , Endometrial Neoplasms/metabolism , Estradiol/pharmacology , Hyaluronan Receptors/genetics , Progesterone/pharmacology , Receptors, Estrogen/metabolism , Tamoxifen/pharmacology , Blotting, Southern , Breast Neoplasms/genetics , Breast Neoplasms/ultrastructure , DNA Primers/chemistry , Endometrial Neoplasms/genetics , Endometrial Neoplasms/ultrastructure , Exons , Female , Gene Expression/drug effects , Humans , Hyaluronan Receptors/biosynthesis , RNA, Messenger/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction , Tamoxifen/analogs & derivatives , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolism
16.
Horm Metab Res ; 33(3): 121-6, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11355743

ABSTRACT

Steroid receptor coactivator 3 (SRC3) functions as a coactivator for nuclear receptor mediated transcriptional activation. It binds to nuclear receptors in a ligand-dependent fashion and recruits other factors such as CBP and p300 to the transactivation complex. Due to its function as activator of nuclear receptors, overexpression of SRC3 might enhance their effects. Gene amplification is a common mechanism that causes overexpression, already described for oncogenes like c-erbB2, c-myc and int2. In this study, SRC3 gene amplification and expression levels were analyzed in 127 sporadic breast carcinomas, 30 endometrial carcinomas and different cell lines (MCF7, HeLa, Ishikawa, T47D, BT-20, SK-BR-3, HEC-1a, RL 95-2, OVCAR3 and A-431). To determine gene amplification and mRNA expression levels, quantitative differential PCR and RT-PCR were performed in combination with fluorescent DNA technology. Gene amplification was not found in any of the breast and endometrial carcinomas, but was found in the carcinoma cell lines MCF7 (10-fold) and HeLa (3-fold). SRC3 overexpression was detected in 13% (3/23) of breast carcinomas and 17% (5/30) of endometrial carcinomas, as well as in MCF7 and HeLa cells. Thus, SRC3 overexpression found in breast and endometrial tumors is not caused by SRC3 gene amplification. A carcinogenic potential provided by SRC3 overexpression has to be elucidated in further studies.


Subject(s)
Breast Neoplasms/metabolism , Endometrial Neoplasms/metabolism , Gene Amplification , Transcription Factors/genetics , Female , Humans , Nuclear Receptor Coactivator 3 , Reverse Transcriptase Polymerase Chain Reaction , Transcriptional Activation , Tumor Cells, Cultured
17.
Int J Cancer ; 92(2): 309-10, 2001 Apr 15.
Article in English | MEDLINE | ID: mdl-11291062

ABSTRACT

Resistance to CD95 (Apo-1/Fas)-mediated apoptosis is a typical feature of breast cancer cells. Recent studies identified deleterious mutations of the CD95 gene not only in a variety of B cell lymphomas but also in a number of solid tumor entities. Therefore, we amplified and sequenced selected regions of the CD95 gene from 48 breast cancer cases and 10 cell lines but no mutation was found. In the presence of both polymorphic alleles, loss of heterozygosity was excluded in 27 informative cases. We conclude, that relevant somatic mutations of the CD95 gene occur, if at all, at a low frequency and are not the primary cause for resistance to CD95-mediated apoptosis in breast cancer.


Subject(s)
Apoptosis , Breast Neoplasms/genetics , fas Receptor/genetics , Breast Neoplasms/pathology , Female , Humans , Mutation , Tumor Cells, Cultured
18.
Lancet ; 356(9243): 1736-7, 2000 Nov 18.
Article in English | MEDLINE | ID: mdl-11095264

ABSTRACT

Successful isolation and genetic testing of fetal cells obtained from maternal blood could eliminate the risks associated with invasive prenatal testing. We used clonal in-vitro expansion of fetal haemopoietic cells and micromanipulation and fluorescent PCR of single colonies to obtain pure fetal colonies from peripheral blood of 12 healthy pregnant women. Of 2966 randomly selected colonies, 42 contained fetal and other cells and, for four women, two to four colonies each contained purely fetal cells. Detection of fetal cells has been hampered by rarity in maternal blood, but with our approach many cells are available for analysis.


Subject(s)
Fetal Blood/cytology , Prenatal Diagnosis/methods , Cells, Cultured , Clone Cells , DNA/genetics , Female , Gestational Age , Humans , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/metabolism , Male , Microsatellite Repeats , Polymerase Chain Reaction , Pregnancy , Random Allocation
19.
Lab Invest ; 80(10): 1513-22, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11045568

ABSTRACT

Alterations of the CDKN2A locus on chromosome 9p21 encoding the p16INK4A cell cycle regulator and the p14ARF1 p53 activator proteins are frequently found in bladder cancer. Here, we present an analysis of 86 transitional cell carcinomas (TCC) to elucidate the mechanisms responsible for inactivation of this locus. Multiplex quantitative PCR analysis for five microsatellites around the locus showed that 34 tumors (39%) had loss of heterozygosity (LOH) generally encompassing the entire region. Of these, 17 tumors (20%) carried homozygous deletions of at least one CDKN2A exon and of flanking microsatellites, as detected by quantitative PCR. Analysis by restriction enzyme PCR and methylation-specific PCR showed that only three specimens, each with LOH across 9p21, had bona fide hypermethylation of the CDKN2A exon 1alpha CpG-island in the remaining allele. Like most other specimens, these three specimens displayed substantial genome-wide hypomethylation of DNA as reflected in the methylation status of LINE L1 sequences. The extent of DNA hypomethylation was significantly more pronounced in TCC with LOH and/or homozygous deletions at 9p21 than in those without (26% and 28%, respectively, on average, versus 11%, p < 0.0015). No association of LOH or homozygous deletions at 9p21 with tumor stage or grade was found. The data indicate that DNA hypermethylation may be rare in TCC and that deletions are the most important mechanism for inactivation of the CDKN2A locus. The predominance of allelic loss may be explained by its correlation with genome-wide DNA hypomethylation, which is thought to favor chromosomal instability and illegitimate recombination.


Subject(s)
Carcinoma, Transitional Cell/genetics , Cyclin-Dependent Kinase Inhibitor p16/genetics , DNA Methylation , Urinary Bladder Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Chromosome Mapping , Female , Humans , Loss of Heterozygosity , Male , Middle Aged , Tumor Cells, Cultured
20.
Z Kardiol ; 89 Suppl 3: 24-35, 2000.
Article in German | MEDLINE | ID: mdl-10810782

ABSTRACT

In patients with acute or chronic myocarditis, arrhythmias are a common and often the only clinical symptom in the natural course of the disease. The potentially malignant tachy- and bradyarrhythmias are of particular significance in the differential diagnosis of sudden cardiac death in myocarditis. Factors responsible for the increased incidence of cardiac arrhythmias are structural changes, parameters of ventricular dynamics and vascular changes. On the one hand, inflammatory processes in the cardiac myocytes and interstitium can lead directly to fluctuations in membrane potential. Fibrosis and scarring of the myocardial tissue and secondary hypertrophy and atrophy of the myocytes favor the development of ectopic pacemakers, late potentials and reentry as a result of inhomogeneous stimulus conduction. Furthermore, parameters of ventricular dynamics such as increased wall tension, increased myocardial oxygen consumption and diminished coronary reserve in the case of disturbed systolic or diastolic left ventricular function also contribute to the increased incidence of arrhythmias. Lastly, vascular factors can further increase the arrhythmogenicity of the inflamed myocardium through the disturbance of micro- and macrovascular perfusion and the resulting myocardial ischemia. Non-invasive rhythmological evaluation by 24 h Holter ECG, measurement of ventricular late potentials and heart rate variability can be used for orienting risk stratification of the at-risk patient with myocarditis. Programmed atrial and ventricular electrophysiological stimulation also has a relatively high predictive value for spontaneous ventricular tachyarrhythmias. It should be emphasized that, at the present time, optimal electrophysiological parameters with a high predictive value do not exist. In a selected patient population, immunosuppressive therapy in addition to conventional antiarrhythmic therapy can lead to the reduction or complete suppression of spontaneous and inducible arrhythmias. Nevertheless, in the interim, further precautionary antiarrhythmic measures such as serial antiarrhythmic treatment, VT ablation and ACID implantation are necessary in patients with malignant cardiac arrhythmias. Right ventricular myocardial biopsy for demonstration or exclusion of myocarditis is an important additional examination which can improve the differential diagnosis and treatment of patients with cardiac arrhythmias of unclear etiology.


Subject(s)
Arrhythmias, Cardiac/etiology , Death, Sudden, Cardiac/etiology , Myocarditis/complications , Adult , Anti-Arrhythmia Agents/therapeutic use , Arrhythmias, Cardiac/drug therapy , Arrhythmias, Cardiac/prevention & control , Biopsy , Child , Electroencephalography , Follow-Up Studies , Heart Rate , Hemodynamics , Humans , Immunosuppressive Agents/therapeutic use , Logistic Models , Myocarditis/pathology , Myocarditis/physiopathology , Myocardium/pathology , Retrospective Studies , Risk Factors , Tachycardia, Ventricular/physiopathology , Tachycardia, Ventricular/prevention & control , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...